EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Multizentrische StudieOpen Access · CC BY-NC 4.0

Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study

Stewart J Tepper, David W Dodick, Michel Lanteri-Minet, David Dolezil, Raquel Gil-Gouveia, Christian Lucas, Karolina Piasecka-Stryczynska, Gyöngyi Szabó, Daniel D Mikol, Mahan Chehrenama, Denise E Chou, Zilu Liu und 1 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.70328 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Stewart J Tepper und 12 weiteren Autor:innen. Beteiligte Einrichtung: The New England Institute for Neurology and Headache, Stamford, Connecticut, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Headache Disorders, Secondary, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen Inc., Amgen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Erenumab‐induced medication overuse headache (MOH) remission in participants with chronic migraine (CM) in a prospective, Phase 4, randomized, placebo‐controlled trial with an open‐label treatment period (OLTP). We present 1‐year results from the combined double‐blind treatment period (DBTP) and OLTP for the stratified nonopioid cohort.

Methods

Participants with CM‐MOH were randomized 1:1:1 to subcutaneous 70 or 140 mg erenumab every 4 weeks (QM) or placebo for the initial 24 weeks (DBTP). Those successfully completing DBTP could continue the 28‐week OLTP, maintaining the same erenumab dose received during DBTP or, if receiving placebo, randomly assigned 1:1 to erenumab 70 or 140 mg QM. OLTP endpoints were exploratory.

Results

Overall, 552 participants received erenumab (70 mg, n = 274; 140 mg, n = 278); 95.3% completed OLTP. One‐year MOH relapse in participants who achieved MOH remission at DBTP Month 6 was 2.7% (3/111) and 2.4% (3/124) with erenumab 70 and 140 mg, respectively; absence of MOH at study end was observed in 69.0% (189/274) and 75.5% (210/278) of participants. Sustained MOH absence over 1 year was reported in 60.5% (107/177) and 68.8% (119/173) of participants, respectively. Sustained improvements in measures of headache days, medication days, and function were observed in both groups. No new safety concerns were identified (grade ≥ 3, 35 [6.3%]; serious, 17 [3.1%]; adverse events leading to treatment discontinuation, 5 [0.9%]).

Conclusions

Erenumab was effective in inducing and sustaining MOH remission and improving function over 1 year. Treatment compliance remained high, with safety events consistent with erenumab's known safety profile. Trial Registration NCT03971071

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHeadache Disorders, SecondaryCalcitonin Gene-Related Peptide Receptor AntagonistsHumansMaleFemaleAdultMiddle AgedDouble-Blind MethodTreatment OutcomeMigraine Disorders

Stichwörter der Autor:innen

calcitonin gene‐related peptideclinical trialerenumabheadache disordersmigraine disorderssecondary

Substanzen

erenumabAntibodies, Monoclonal, HumanizedCalcitonin Gene-Related Peptide Receptor Antagonists

Autor:innen und Institutionen

  • The New England Institute for Neurology and Headache, Stamford, Connecticut, USA.
  • Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Atria Academy of Science and Medicine, New York, New York, USA.
  • Pain Department and FHU InovPain, Centre Hospitalier Universitaire de Nice-Côte Azur and University, Nice, France.
  • Inserm U1107, Neuro-Dol, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Prague Headache Center, DADO MEDICAL Sro, Prague, Czech Republic.

Förderung

  • Amgen Inc.
  • Amgen

Zitieren

APA

Tepper, S. J., Dodick, D. W., Lanteri-Minet, M., Dolezil, D., Gil-Gouveia, R., Lucas, C., Piasecka-Stryczynska, K., Szabó, G., Mikol, D. D., Chehrenama, M., Chou, D. E., Liu, Z., & da Silva Lima, G. P. (2025). Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study. European Journal of Neurology. https://doi.org/10.1111/ene.70328

Vancouver

Tepper SJ, Dodick DW, Lanteri-Minet M, Dolezil D, Gil-Gouveia R, Lucas C, et al. Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study. European Journal of Neurology. 2025. doi:10.1111/ene.70328

BibTeX
@article{Tepper2025,
  author = {Tepper, Stewart J and Dodick, David W and Lanteri-Minet, Michel and Dolezil, David and Gil-Gouveia, Raquel and Lucas, Christian and Piasecka-Stryczynska, Karolina and Szabó, Gyöngyi and Mikol, Daniel D and Chehrenama, Mahan and Chou, Denise E and Liu, Zilu and da Silva Lima, Gabriel Paiva},
  title = {Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo‐Controlled Study},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70328}
}
Kostenlos starten →